Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations. Methods: We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows: age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month. Results: In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients. Patients who answered “Decided by consultation with physicians” had significantly higher satisfaction levels and DAI-10 scores compared to those who answered “Decided by physicians” (4.11 ± 0.77 vs. 3.80 ± 1.00, p = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, p ＜ 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, p ＜ 0.001). Conclusion: No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients’ individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.
Abstract
Objective: To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations. Methods: We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows: age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month. Results: In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients. Patients who answered “Decided by consultation with physicians” had significantly higher satisfaction levels and DAI-10 scores compared to those who answered “Decided by physicians” (4.11 ± 0.77 vs. 3.80 ± 1.00, p = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, p ＜ 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, p ＜ 0.001). Conclusion: No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients’ individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.
참고문헌 (20)
- Robinson D, "Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
- Caseiro O, "Predicting relapse after a first episode of non-affective psychosis : a threeyear follow-up study", J Psychiatr Res, 46, pp.1099~1105 (2012)
- Byerly M, "A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia", Psychiatry Res, 133, pp.129~133 (2005)
- Lacro JP, "Prevalence of and risk factors for medication nonadherence in patients with schizophrenia : a comprehensive review of recent literature", J Clin Psychiatry, 63, pp.892~909 (2002)
- Osterberg L, "Adherence to medication", N Engl J Med, 353, pp.487~497 (2005)
- Schiele JT, "Difficulties swallowing solid oral dosage forms in a general practice population : prevalence, causes, and relationship to dosage forms", Eur J Clin Pharmacol, 69, pp.937~948 (2013)
- Hasan A, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, part 2 : update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects", World J Biol Psychiatry, 14, pp.2~44 (2013)
- Caroli F, "Opinions of French patients with schizophrenia regarding injectable medication", Patient Prefer Adherence, 5, pp.165~171 (2011)
- Hogan TP, "A self-report scale predictive of drug compliance in schizophrenics : reliability and discriminative validity", Psychol Med, 13, pp.177~183 (1983)
- Miyata R, "Drug compliance in schizophrenia", Jpn J Clin Psychiatry, 28, pp.265~275 (1999)
- Witticke D, "Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics", Patient Prefer Adherence, 6, pp.679~684 (2012)
- Charles C, "Shared decision-making in the medical encounter : what does it mean?(or it takes at least two to tango)", Soc Sci Med, 44, pp.681~692 (1997)
- Kishimoto T, "Long-acting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
- Shariff ZB, "Does the formulation of oral solid dosage forms affect acceptance and adherence in older patients? A mixed methods systematic review", J Am Med Dir Assoc, 21, pp.1015~1023 (2020)
- Masakazu Hatano, "Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia", Clinical Psychopharmacology and Neuroscience, 15(2), pp.132~137 (2017), 대한정신약물학회[DOI]
- Kinoshita T, "Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, doubleblind, 6-week, placebo-controlled study", Psychopharmacology(Berl), 233, pp.2663~2674 (2016)
- Gerrits M, "Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects", Biopharm Drug Dispos, 31, pp.351~357 (2010)
- Fleischhacker WW, "Factors influencing compliance in schizophrenia patients", J Clin Psychiatry, 64(Suppl 16), pp.10~13 (2003)
- Xia J, "Psychoeducation for schizophrenia", Cochrane Database Syst Rev, (6), pp.CD002831~ (2011)
- Kavanagh K, "Educating acute inpatients about their medication : is it worth it? An exploratory study of group education for patients on a psychiatric intensive care unit", J Ment Health, 12, pp.71~80 (2003)